Simulations Plus Total Current Liabilities 2010-2025 | SLP
Simulations Plus total current liabilities from 2010 to 2025. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Simulations Plus Annual Total Current Liabilities (Millions of US $) |
2024 |
$12 |
2023 |
$12 |
2022 |
$8 |
2021 |
$12 |
2020 |
$6 |
2019 |
$5 |
2018 |
$5 |
2017 |
$2 |
2016 |
$2 |
2015 |
$4 |
2014 |
$1 |
2013 |
$1 |
2012 |
$1 |
2011 |
$1 |
2010 |
$1 |
2009 |
$1 |
Simulations Plus Quarterly Total Current Liabilities (Millions of US $) |
2025-02-28 |
$11 |
2024-11-30 |
$10 |
2024-08-31 |
$12 |
2024-05-31 |
$11 |
2024-02-29 |
$15 |
2023-11-30 |
$9 |
2023-08-31 |
$12 |
2023-05-31 |
$9 |
2023-02-28 |
$6 |
2022-11-30 |
$8 |
2022-08-31 |
$8 |
2022-05-31 |
$6 |
2022-02-28 |
$9 |
2021-11-30 |
$10 |
2021-08-31 |
$12 |
2021-05-31 |
$7 |
2021-02-28 |
$7 |
2020-11-30 |
$5 |
2020-08-31 |
$6 |
2020-05-31 |
$8 |
2020-02-29 |
$5 |
2019-11-30 |
$6 |
2019-08-31 |
$5 |
2019-05-31 |
$5 |
2019-02-28 |
$5 |
2018-11-30 |
$5 |
2018-08-31 |
$5 |
2018-05-31 |
$5 |
2018-02-28 |
$6 |
2017-11-30 |
$6 |
2017-08-31 |
$2 |
2017-05-31 |
$1 |
2017-02-28 |
$2 |
2016-11-30 |
$2 |
2016-08-31 |
$2 |
2016-05-31 |
$4 |
2016-02-29 |
$4 |
2015-11-30 |
$4 |
2015-08-31 |
$4 |
2015-05-31 |
$2 |
2015-02-28 |
$1 |
2014-11-30 |
$2 |
2014-08-31 |
$1 |
2014-05-31 |
$2 |
2014-02-28 |
$1 |
2013-11-30 |
$1 |
2013-08-31 |
$1 |
2013-05-31 |
$1 |
2013-02-28 |
$1 |
2012-11-30 |
$1 |
2012-08-31 |
$1 |
2012-05-31 |
$2 |
2012-02-29 |
$3 |
2011-11-30 |
$1 |
2011-08-31 |
$1 |
2011-05-31 |
$2 |
2011-02-28 |
$1 |
2010-11-30 |
$1 |
2010-08-31 |
$1 |
2010-05-31 |
$1 |
2010-02-28 |
$1 |
2009-11-30 |
$1 |
2009-08-31 |
$1 |
2009-05-31 |
$1 |
2009-02-28 |
$1 |
Sector |
Industry |
Market Cap |
Revenue |
Computer and Technology |
Computer Software |
$0.620B |
$0.070B |
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|